Which federal agency does American Medical Association comment on most?

American Medical Association is most active at the Food and Drug Administration.

← OpenPolis Sign in

American Medical Association

Unclaimed

Industry

Nonprofit Organization Management

Staff

2,600

330 North Wabash Avenue, Chicago, Illinois

Phone

+1 800-621-8335

Website

ama-assn.org

Engagement overview

American Medical Association has filed 287 public comments across 235 dockets at 24 federal agencies, most actively at the Food and Drug Administration.

American Medical Association

Engagement overview

Is this your organization?

Agency footprint

Dockets · FDA (76)

List of Bulk Drug Substances For Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Notice

Food Safety and Inspection Service Ultra-Processed Foods; Request for Information

Food Labeling: Front-of-Package Nutrition Information

Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations; Draft Guidance for Industry and Food and Drug Administration Staff; Availability

Approach for Improving the Performance Evaluation of Pulse Oximeter Devices Taking Into Consideration Skin Pigmentation, Race and Ethnicity

Recommendations for Determining Risk of Human Immunodeficiency Virus (HIV) Infection for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps); Draft Guidance for Industry

Voluntary Sodium Reduction Goals: Target Mean and Recommended Maximum Concentrations for Sodium in Commercially Processed, Packaged, and Prepared Foods

Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability

Considerations in Demonstrating Interchangeability With a Reference Product

Collection of Race and Ethnicity Data in Clinical Trials

Medical Devices; Laboratory Developed Tests

Questions and Answers About Dietary Guidance Statements in Food Labeling: Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request

Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products

Select Updates for the Breakthrough Devices Program Guidance: Reducing Disparities in Health and Health Care; Draft Guidance for Industry and Food and Drug Administration Staff; Availability

Reconsidering Mandatory Opioid Prescriber Education Through a Risk Evaluation and Mitigation Strategy (REMS) in an Evolving Opioid Crisis; Public Workshop; Request for Comments

Federal Registers, Written and Electronic Submissions (that do not include a Docket Number or ID_2021)

Prescription Drug User Fee Act

Importation of Prescription Drugs

Importation of Certain FDA-Approved Human Prescription Drugs, Including Biological Products, under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry; Availability

Request for Comments on the Office of Minority Health and Health Equity Strategic Priorities

Clinical and Patient Decision Support Software

Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) - Discussion Paper and Request for Feedback

Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments

Fostering Medical Innovation: A Plan for Digital Health Devices; Software Precertification Pilot Program

Eliminating Youth Electronic Cigarette and Other Tobacco Product Use: The Role for Drug Therapies; Public Hearing; Request for Comments

Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions; Public Meeting; Request for Comments

Insanitary Conditions at Compounding Facilities

Facilitating Competition and Innovation in the Biological Products Marketplace; Public Hearing; Request for Comments

Expansion of the Abbreviated 510(k) Program: Demonstrating Substantial Equivalence through Performance Criteria; Draft Guidance for Industry and Food and Drug Administration Staff; Availability

Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act

Review of Existing General Regulatory and Information Collection Requirements of the Food and Drug Administration

Opioid Policy Steering Committee

Amphetamines

Food Labeling: Revision of the Nutrition and Supplement Facts Labels

Administering the Hatch-Waxman Amendments: Ensuring an Appropriate Balance Between Innovation and Access

FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioids

Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products

General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products

Blood Donor Deferral Policy for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Establishment of a Public Docket

Use of Public Human Genetic Variant Databases to Support Clinical Validity for Next Generation Sequencing (NGS)-Based In Vitro Diagnostics; Draft Guidance for Stakeholders and Food and Drug Administration Staff; Availability

Use of Standards in FDA Regulatory Oversight of Next Generation Sequencing (NGS)-Based In Vitro Diagnostics (IVDs) Used for Diagnosing Germline Diseases

Blood Products Advisory Committee

Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application

Strengthening the National Medical Device Postmarket Surveillance System; Notice of Public Meeting

Optimizing Regulatory Oversight of Next Generation Sequencing Diagnostic Tests Public Workshop; Request for Comments

Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products

Reference Daily Intake&Daily Reference Values/Food Labeling - CLOSED

FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs)

Legal Status of Approved Labeling for Prescription Drugs - CLOSED

Protection of Human Subjects - closed

Tentative Determination Regarding Partially Hydrogenated Oils; Request for Comments and for Scientific Data and Information

Regulate Labeling of Opioid Analgesics - CLOSED

Food and Drug Administration Drug Shortages Task Force and Strategic Plan; Request for Comments

Medical Devices

Using Innovative Technologies and Other Conditions of Safe Use To Expand Which Drug Products Can Be Considered Nonprescription

New Animal Drugs; Cephalosporin Drugs; Extralabel Animal Drug Use; Order of Prohibition

Approaches to Reducing Sodium Consumption

Required Warnings for Cigarette Packages & Advertisements

Draft Guidance for Industry on Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies; Availability

Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee; Notice of Meeting

Biosimilar and Interchangeable Biological Products

The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals

Tobacco Product Advertising and Promotion to Youth and Racial and Ethnic Minority Populations; Request for Comments

Assessing Consumer Perceptions of Health Claims; Public Meeting; Request for Comments

Regulation of Tobacco Products; Request for Comments

Treatment of Narcotic Dependence

Current Good Manufacturing Practice in Manufacturing, Packing, or Holding Dietary Supplements

Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling

Electronic Distribution of Prescribing Information for Prescription Drug Products; Public Hearing

Requirements for Human Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use

Labeling for Human Prescription Drug/Biologic Products-CLOSED

Guidance for Industry on Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices

Requesting Expansion of Availability of Nicotine Replacement Therapy to Consumers Who Use Tobacco - CLOSED

Salt and Sodium; Petition to Revise the Regulatory Status of Salt and Establish Food Labeling Requirements Regarding Salt and Sodium; Public Hearing; Request for Comments